As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the pharmaceutical and healthcare industry around the world to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2022 and its open-access platform is enabling more than 5,950 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."
Enabling more than 5,950 Innovative customers from more than 30 Countries
Small Molecule Drug R&D and Manufacturing
Cell Therapy
and Gene Therapy
Drug R&D and Medical
Device Testing
Clinical
Services
Small Molecule Drug R&D and Manufacturing
To Become the Most Comprehensive Capability and Technology Platform in the Global Pharmaceutical and Healthcare Industry
WuXi AppTec Reports Record Results in 2022
WuXi AppTec Named “Industry Mover” in S&P Global Sustainability Yearbook 2023
WuXi AppTec Named to the 2022 Dow Jones Sustainability World Index
WuXi AppTec Receives 2022 Global Contract Research, Development and Manufacturing Organization Company of the Year Award from Frost & Sullivan
WuXi AppTec Reports Record Year-to-Date Results in 2022, Third Quarter Revenue over RMB10 Billion
WuXi STA Opens First High Potency Oral Drug Product Manufacturing Facility
